Albert Parker Net Worth

The estimated Net Worth of Albert P Parker is at least $705 Mille dollars as of 15 February 2023. Mr. Parker owns over 3,173 units of Oncocyte stock worth over $703,756 and over the last 6 years he sold OCX stock worth over $1,713. In addition, he makes $0 as Chief Operating Officer at Oncocyte.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Parker OCX stock SEC Form 4 insiders trading

Albert has made over 2 trades of the Oncocyte stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,173 units of OCX stock worth $1,713 on 15 February 2023.

The largest trade he's ever made was buying 5,000 units of Oncocyte stock on 3 August 2020 worth over $6,650. On average, Albert trades about 817 units every 93 days since 2019. As of 15 February 2023 he still owns at least 227,018 units of Oncocyte stock.

You can see the complete history of Mr. Parker stock trades at the bottom of the page.

Albert Parker biography

Albert P. Parker J.D. serves as Chief Operating Officer of the Company. Prior to joining Oncocyte, Mr. Parker was the managing shareholder of GC Legal Advisors, a law firm established to provide or supplement in-house legal support on an interim, part-time, or project basis for companies operating across various industries. Mr. Parker also served as Executive Vice President, General Counsel and Corporate Secretary of Sunovion Pharmaceuticals from 2013 to 2014. From 2000-2010, Mr. Parker served in a number of management and legal positions at the Vice President or Senior Vice President and Chief Counsel level at Wyeth Pharmaceuticals (now a part of Pfizer). Before joining Wyeth Pharmaceuticals, Mr. Parker served as an Assistant General Counsel at Warner-Lambert Company, and was a partner in a Philadelphia law firm. Mr. Parker holds a J.D. from the University of Pennsylvania Law School and a B.A. from Pennsylvania State University.

What's Albert Parker's mailing address?

Albert's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.

Insiders trading at Oncocyte

Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin... e Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.

What does Oncocyte do?

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.

Complete history of Mr. Parker stock trades at Zynerba Pharmaceuticals Inc e Oncocyte

Oncocyte executives and stock owners

Oncocyte executives and other stock owners filed with the SEC include:

• Ronald Andrews,
  President, Chief Executive Officer, Director
• Lyndal Hesterberg,
  Chief Scientific Officer
• Mitchell Levine,
  Chief Financial Officer
• Ronald A. Andrews Jr.,
  CEO, Pres & Director
• Cavan Redmond,
  Independent Chairman of the Board
• Andrew Last,
  Independent Director
• Andrew Arno,
  Independent Director
• Melinda Griffith,
  Independent Director
• Bob Yedid,
  Investor Relations
• Douglas Ross,
  Chief Medical Officer
• Padma Sundar,
  Senior Vice President - Marketing and Market Access
• Tony Kalajian,
  Senior Vice President, Chief Accounting Officer
• Albert Parker,
  Chief Operating Officer
• Dr. Michael D. West Ph.D.,
  Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.
• Dr. Ekkehard Schutz M.D., Ph.D.,
  Chief Technology Officer
• Robert S. Seitz,
  Head of Immune Oncology
• Li Yu,
  VP, Controller & Principal Accounting Officer
• Gisela A. Paulsen,
  Chief Operating Officer
• Sara Riordan,
  Director of Medical Education
• Dr. Michael D. West,
  Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.
• Dr. Douglas T. Ross M.D., Ph.D.,
  Chief Science Officer
• William Annett,
  Advisor
• Gisela Paulsen,
  Former President and COO
• Vida Investments, Llc Kamen...,
  
• Karen B. Chapman,
  Vice President of Research
• Alfred D Kingsley,
  Director
• Don M Bailey,
  Director
• William Annett,
  President and CEO
• Michael D West,
  Director
• Kristine C. Mechem,
  VP of Marketing
• Partners, L.P.Broadwood Cap...,
  
• Anish M. John,
  Chief Financial Officer
• Aditya P. Mohanty,
  Director
• Cell Therapeutics, Inc. Lin...,
  
• James Yang Liu,
  Sr Dir., Cntlr, PAO, Int PFO
• Jennifer L. Carter,
  Director
• Li Yu,
  VP Cntrllr/Prncpl Acctng Offcr
• Partners, L.P.Bradsher Neal...,
  
• Lou Silverman,
  Director
• Josh Riggs,
  CEO and President
• John Peter Gutfreund,
  
• Andrea S. James,
  Chief Financial Officer